Aurora Cannabis (ACB) Expected to Announce Quarterly Earnings on Wednesday

Aurora Cannabis (NASDAQ:ACB) is projected to post its Q1 2027 results before the market opens on Wednesday, August 5th. Analysts expect Aurora Cannabis to announce earnings of ($0.13) per share and revenue of $47.45 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Aurora Cannabis (NASDAQ:ACB) last released its quarterly earnings data on Thursday, June 11th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.14. Aurora Cannabis had a positive return on equity of 0.10% and a negative net margin of 33.57%.The business had revenue of $60.98 million for the quarter, compared to analyst estimates of $54.42 million. On average, analysts expect Aurora Cannabis to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Aurora Cannabis Stock Down 0.7%

Shares of NASDAQ:ACB opened at $2.72 on Wednesday. The stock has a 50-day simple moving average of $3.01 and a 200-day simple moving average of $3.42. The stock has a market capitalization of $166.84 million, a P/E ratio of -1.74 and a beta of 0.57. Aurora Cannabis has a 1 year low of $2.56 and a 1 year high of $6.66. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.32 and a current ratio of 5.94.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ACB. Weiss Ratings raised shares of Aurora Cannabis from a “sell (d-)” rating to a “sell (d)” rating in a research report on Tuesday, June 16th. Wall Street Zen raised shares of Aurora Cannabis from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aurora Cannabis has a consensus rating of “Hold”.

Hedge Funds Weigh In On Aurora Cannabis

Several hedge funds and other institutional investors have recently bought and sold shares of ACB. Two Sigma Investments LP lifted its position in shares of Aurora Cannabis by 7,412.0% during the third quarter. Two Sigma Investments LP now owns 1,149,869 shares of the company’s stock worth $6,853,000 after purchasing an additional 1,134,562 shares in the last quarter. Millennium Management LLC grew its holdings in Aurora Cannabis by 563.7% during the 3rd quarter. Millennium Management LLC now owns 391,782 shares of the company’s stock valued at $2,339,000 after purchasing an additional 332,750 shares in the last quarter. Trexquant Investment LP purchased a new stake in Aurora Cannabis during the 4th quarter worth $590,000. UBS Group AG increased its stake in Aurora Cannabis by 136.8% during the 3rd quarter. UBS Group AG now owns 184,190 shares of the company’s stock worth $1,098,000 after buying an additional 106,391 shares during the period. Finally, Tidal Investments LLC increased its stake in Aurora Cannabis by 6.0% during the 2nd quarter. Tidal Investments LLC now owns 1,509,483 shares of the company’s stock worth $6,400,000 after buying an additional 86,045 shares during the period. 47.63% of the stock is owned by institutional investors and hedge funds.

About Aurora Cannabis

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.